NASH is a disease that combines an accumulation of fat in the liver with inflammation leading to degeneration of liver cells.

In a second stage, fibrosis appears, which is only the appearance of scar tissue replacing dead liver cells. As this fibrosis increases, it is possible to reach an almost irreversible stage where scar tissue occupies such a place in the liver that it can no longer function properly: this is cirrhosis, which can itself lead to hepatocarcinoma.

To date, there is no specific medication for the treatment of these various symptoms and even less for the treatment of the cause of the disease which is due to poor nutrition. There are drugs at an advanced stage of development that will only treat some of the symptoms of this disease and it is already anticipated that combinations of treatments will be necessary.

The ADPIF project aims to develop therapeutic peptides that will act, via an original mode of action, upstream of different processes induced in this disease and thus allow better patient care with a single treatment and monthly or even quarterly administration.